The 340B drug pricing program has entered a new era of scrutiny, with pharmaceutical manufacturers, legislators, and safety-net providers all focused on program integrity. As covered entities navigate complex administrative dispute resolution processes and increasing oversight, maintaining ethical standards has never been more crucial for 340B program participants who dispense discounted drugs to eligible patients and provide comprehensive services.
Edward Vargas, founder of Virtue 340B, emphasizes this point: “It’s always important to know when to say no. If it’s difficult for an independent, unbiased party to infer that your covered entity is maintaining responsibility of care and meeting the requirements of the 340B statute, then it probably shouldn’t be captured.” Read More >
